MarketPeel
Insider Trading Intelligence
Pricing
…
MU

Marshall Urist

RPRX
EVP, RESEARCH & INVESTMENTS · ROYALTY PHARMA PLC · CIK 0001838139
FILING MIX · LIFETIME24%/76%
BUYS
10
SELLS
32
TOTAL VALUE
$18.10M
COMPANIES
1
ACTIVE SINCE
May 2021
HOLDINGS NOW
0
AVG SELL PX
$41.92
TRADE KIND
SHOWING 42 / 42
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
22 backtested trades · 8 horizons · 28 pending
Forward-return performance of every backtestable P/S trade by Marshall Urist, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d22+68.18%-0.10%+0.48%-0.58%-1.15%—
14d22+36.36%+1.17%+0.65%+0.52%+0.05%—
30d22+45.45%+2.39%+1.05%+1.34%+0.17%—
60d22+31.82%+4.64%+0.15%+4.49%+5.17%—
90d22+40.91%+8.07%+1.31%+6.76%+15.62%—
180d22(4 pending)+38.89%+14.24%+7.48%+0.02%-9.29%—
1y22(12 pending)+100.00%-13.82%+7.09%-20.91%-14.93%—
2y22(12 pending)+100.00%-24.14%+23.87%-48.01%-47.11%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
RPRX · 0 shares · as of Jul 1, 2026
0339,132678,2641,017,3961,356,52820222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
2026
FLOW · 10 buys / 32 sellsCOVERAGE · 22 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
RPRX
ROYALTY PHARMA PLC
SALE10b5-1
10b5-1 plan
9,099$55.88$508.5K0Jul 1, 2026Jul 2, 2026 ↗View →
RPRX
ROYALTY PHARMA PLC
SALE10b5-1
10b5-1 plan
9,098$55.18$502.1K9,099Jun 24, 2026Jun 25, 2026 ↗View →
RPRX
ROYALTY PHARMA PLC
SALE10b5-1
10b5-1 plan
13,684$52.75$721.8K18,197May 20, 2026May 21, 2026 ↗View →
RPRX
ROYALTY PHARMA PLC
SALE10b5-1
10b5-1 plan
13,684$53.06$726.1K31,881May 14, 2026May 15, 2026 ↗View →
RPRX
ROYALTY PHARMA PLC
PURCHASEGRANT
Stock grant
18,197——45,565May 6, 2026May 8, 2026 ↗View →
RPRX
ROYALTY PHARMA PLC
PURCHASEGRANT
Stock grant
19,970——27,368Feb 11, 2026Feb 13, 2026 ↗View →
RPRX
ROYALTY PHARMA PLC
SALE10b5-1
10b5-1 plan
20,000$41.09$821.8K0Jan 30, 2026Feb 2, 2026 ↗View →
RPRX
ROYALTY PHARMA PLC
SALE10b5-1
10b5-1 plan
20,000$40.26$805.1K20,000Jan 23, 2026Jan 26, 2026 ↗View →
RPRX
ROYALTY PHARMA PLC
SALE10b5-1
10b5-1 plan
20,000$39.52$790.3K40,000Jan 16, 2026Jan 20, 2026 ↗View →
RPRX
ROYALTY PHARMA PLC
SALE10b5-1
10b5-1 plan
20,000$40.78$815.6K60,000Jan 9, 2026Jan 13, 2026 ↗View →
RPRX
ROYALTY PHARMA PLC
SALE10b5-1
10b5-1 plan
20,000$38.48$769.6K80,000Jan 2, 2026Jan 6, 2026 ↗View →
RPRX
ROYALTY PHARMA PLC
SALE10b5-1
10b5-1 plan
20,000$39.32$786.4K100,000Dec 26, 2025Dec 29, 2025 ↗View →
RPRX
ROYALTY PHARMA PLC
SALE10b5-1
10b5-1 plan
20,000$38.38$767.6K120,000Dec 19, 2025Dec 22, 2025 ↗View →
RPRX
ROYALTY PHARMA PLC
SALE10b5-1
10b5-1 plan
20,000$38.32$766.4K140,000Dec 16, 2025Dec 17, 2025 ↗View →
RPRX
ROYALTY PHARMA PLC
SALE10b5-1
10b5-1 plan
18,242$39.15$714.2K7,398Dec 5, 2025Dec 9, 2025 ↗View →
RPRX
ROYALTY PHARMA PLC
SALE10b5-1
10b5-1 plan
23,334$39.15$913.6K160,000Dec 5, 2025Dec 9, 2025 ↗View →
RPRX
ROYALTY PHARMA PLC
SALE10b5-1
10b5-1 plan
18,242$39.90$727.9K25,640Dec 1, 2025Dec 3, 2025 ↗View →
RPRX
ROYALTY PHARMA PLC
SALE10b5-1
10b5-1 plan
23,333$39.93$931.6K183,334Dec 1, 2025Dec 3, 2025 ↗View →
RPRX
ROYALTY PHARMA PLC
PURCHASE
EVP, Research & Investments
160,000——206,667Nov 7, 2025Nov 7, 2025 ↗View →
RPRX
ROYALTY PHARMA PLC
SALE
EVP, Research & Investments
16,000——247,412Nov 7, 2025Nov 7, 2025 ↗View →
RPRX
ROYALTY PHARMA PLC
PURCHASEGRANT
Stock grant
4,626——43,882Nov 5, 2025Nov 7, 2025 ↗View →
RPRX
ROYALTY PHARMA PLC
SALEGRANT
Gift
3,000——263,412Aug 8, 2025Aug 8, 2025 ↗View →
RPRX
ROYALTY PHARMA PLC
PURCHASEGRANT
Stock grant
2,772——39,256Aug 6, 2025Aug 8, 2025 ↗View →
RPRX
ROYALTY PHARMA PLC
PURCHASEGRANT
Stock grant
1,356,528——1,356,528May 16, 2025May 20, 2025 ↗View →
RPRX
ROYALTY PHARMA PLC
PURCHASEGRANT
Stock grant
36,484——83,151May 8, 2025May 9, 2025 ↗View →
RPRX
ROYALTY PHARMA PLC
SALEGRANT
Gift
2,182——126,412Aug 12, 2024Aug 12, 2024 ↗View →
RPRX
ROYALTY PHARMA PLC
SALE
EVP, Research & Investments
23,333$37.30$870.2K46,667Feb 22, 2023Feb 24, 2023 ↗View →
RPRX
ROYALTY PHARMA PLC
PURCHASE
EVP, Research & Investments
70,000——70,000Feb 17, 2023Feb 17, 2023 ↗View →
RPRX
ROYALTY PHARMA PLC
SALE
EVP, Research & Investments
7,000——128,594Feb 17, 2023Feb 17, 2023 ↗View →
RPRX
ROYALTY PHARMA PLC
SALE
EVP, Research & Investments
19,734$43.20$852.5K0Jul 26, 2022Jul 27, 2022 ↗View →
RPRX
ROYALTY PHARMA PLC
SALE
EVP, Research & Investments
3,600$43.05$155.0K19,734Jul 25, 2022Jul 27, 2022 ↗View →
RPRX
ROYALTY PHARMA PLC
SALE
EVP, Research & Investments
23,333$43.19$1.01M23,334Jun 24, 2022Jun 24, 2022 ↗View →
RPRX
ROYALTY PHARMA PLC
SALE
EVP, Research & Investments
23,333$39.85$929.8K46,667May 16, 2022May 16, 2022 ↗View →
RPRX
ROYALTY PHARMA PLC
SALE
EVP, Research & Investments
7,000——205,594May 11, 2022May 11, 2022 ↗View →
RPRX
ROYALTY PHARMA PLC
PURCHASE
EVP, Research & Investments
70,000——70,000May 11, 2022May 11, 2022 ↗View →
RPRX
ROYALTY PHARMA PLC
SALE
EVP & Co-Head of R&I
16,568$47.02$779.1K0Jun 7, 2021Jun 8, 2021 ↗View →
RPRX
ROYALTY PHARMA PLC
SALE
EVP & Co-Head of R&I
16,566$45.13$747.7K16,568Jun 4, 2021Jun 8, 2021 ↗View →
RPRX
ROYALTY PHARMA PLC
SALE
EVP & Co-Head Research & Inv.
14,566$41.52$604.9K33,134Jun 2, 2021Jun 4, 2021 ↗View →
RPRX
ROYALTY PHARMA PLC
SALE
EVP & Co-Head Research & Inv.
100$41.00$4.1K47,700May 21, 2021May 24, 2021 ↗View →
RPRX
ROYALTY PHARMA PLC
SALE
EVP & Co-Head Research & Inv.
1,900$41.08$78.1K47,800May 20, 2021May 24, 2021 ↗View →
RPRX
ROYALTY PHARMA PLC
SALE
EVP & Co-Head Research & Inv.
4,970——142,594May 7, 2021May 11, 2021 ↗View →
RPRX
ROYALTY PHARMA PLC
PURCHASE
EVP & Co-Head Research & Inv.
49,700——49,700May 7, 2021May 11, 2021 ↗View →
Other insiders · RPRX
Loading peer insiders…
About this filer
CIK 0001838139
ROLE
EVP, Research & Investments
PRIMARY
RPRX
COMPANIES
1
ACTIVE SINCE
May 2021
MARKETPEEL · /INSIDER/0001838139DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback